Market Overview

With Rite Aid Uncertainty Behind It, Could Walgreens Go Shopping?

With Rite Aid Uncertainty Behind It, Could Walgreens Go Shopping?

For more than two years, pharmaceutical giant Walgreens Boots Alliance Inc (NASDAQ: WBA) has been "tap dancing horizontally" with smaller rival Rite Aid Corporation (NYSE: RAD). In the end, Rite Aid agreed to sell Walgreens 1,932 of its stores in a $4.4-billion deal that now frees up Walgreens to potentially pursue other acquisitons. 

The Analyst

Deutsche Bank's Glen Santangelo initiated coverage of Walgreens Boots' stock with a Hold rating and $78 price target.

The Thesis

The competitive landscape in the pharmaceutical and retail space implies that standing still is not a viable option, Santangelo said in the initiation note. (See Santangelo's track record here.)

Walgreens' management team acknowledges and recognizes this reality and publicly commented multiple times that the U.S. pharmaceutical supply chain needs to be vertically integrated to lower costs and increase efficiency, the analyst said. 

The deal with Rite Aid is a step forward for Walgreens to improve its structure, but the "watered down" outcome did act as a destruction at a somewhat expensive cost, Santangelo said. At its core, the deal does represent a new tailwind for growth, he said. 

Looking forward, Walgreens' could seek a more aggressive acquisition and look to vertically integrate or at the very least partner with others in the supply chain channel, according to Deutsche Bank. The company is backed by sufficient cash flow and balance sheet flexibility, as well as a management team that "thinks strategically" and won't shy away from remaining aggressive, Santangelo said. 

The analyst's Hold rating is mostly related to industrywide challenges that are impacting both the U.S. and international retail businesses, which are showing subpar growth rates, according to Deutsche Bank. 

Price Action

Shares of Walgreens were trading lower by more than 1 percent Monday afternoon and are down nearly 15 percent since the start of 2017.

Related Links:

Walgreens: A Weak Stock Is A Weak Stock

Walgreens Pick Up: Selloff Offers 40% Upside

Photo courtesy of Theopolisme/Wikipedia.

Latest Ratings for WBA

Oct 2019DowngradesOverweightNeutral
Oct 2019MaintainsUnderperform
Aug 2019MaintainsEqual-Weight

View More Analyst Ratings for WBA
View the Latest Analyst Ratings

Posted-In: Deutsche Bank Glen Santangelo PharmaceuticalAnalyst Color Price Target Initiation Top Stories Analyst Ratings Best of Benzinga


Related Articles (RAD + WBA)

View Comments and Join the Discussion!

Latest Ratings

ABBBarclaysInitiates Coverage On
DPLOWilliam BlairUpgrades
SUPVItau BBADowngrades
GGALItau BBADowngrades
BMAItau BBADowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Deutsche Bank Downgrades Old Dominion, Projects 20% Downside

Netflix Chief: There Will Be More 'House of Cards'